- Home
- ZBAI vs AEON Comparison
ZBAI vs AEON Comparison
Compare ZBAI & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$7.50
HOLD
Current Price
$0.84
Company Overview
Basic Information| Metric | ZBAI | AEON |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 10.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBAI | AEON |
|---|---|---|
| Price | $7.50 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.20 |
| AVG Volume (30 Days) | 6.0K | ★ 210.6K |
| Earning Date | 12-15-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.55 | N/A |
| 52 Week Low | $4.83 | $0.38 |
| 52 Week High | $45.00 | $64.80 |
Technical Indicators
Market Signals| Indicator | ZBAI | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 51.55 |
| Support Level | $6.66 | $0.72 |
| Resistance Level | $7.93 | $0.79 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 71.90 | 81.12 |
Price Performance
Historical Comparison ZBAI
AEON
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.